Evidence map›Paper›PMID 40719068›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Alternative Models for Anticancer Drug Discovery From Natural Products Using Binary Tumor-Microenvironment-on-a-Chip.

Youngwon Kim, Si Hyeon Chae, Dahae Lee, Bum Soo Lee, Jiseok Lim, Hyo-Il Jung, Ki Hyun Kim, Bongseop Kwak

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Youngwon KimSchool of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 13722, Republic of Korea.
Si Hyeon ChaeSchool of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Dahae LeeCollege of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
Bum Soo LeeSchool of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Jiseok LimSchool of Mechanical Engineering, Yeungnam University, 280 Daehak-ro, Gyeongsan-si, Gyeongsangbuk-do, 38541, Republic of Korea.
Hyo-Il JungSchool of Mechanical Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 13722, Republic of Korea.
Ki Hyun KimSchool of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Bongseop KwakCollege of Medicine, Dongguk University, 32 Dongguk-ro, Ilsandong-gu, Goyangsi, Gyeonggi-do, 10326, Republic of Korea.ORCID https://orcid.org/0000-0003-2809-9113

Funding

Korea Ministry of Environment (MOE) RS-2025-02223058Ministry of Science, ICT and Future Planning RS-2019-NR040057Ministry of Science, ICT and Future Planning RS-2021-NR059240
6 · The paper itself

Abstract

The efficacy evaluation of anticancer drugs derived from natural products has traditionally relied on animal models, highlighting the need for more efficient preclinical assessment platforms. In this study, a binary tumor-microenvironment-on-a-chip (T-MOC) system is introduced to assess the therapeutic potential of illudin S and roridin E, two cytotoxic compounds derived from Omphalotus japonicus and Podostroma cornu-damae, respectively. The binary T-MOC model integrates independently developed vascular and invasive ductal carcinoma compartments, effectively mimicking in vivo drug delivery barriers and physiological dynamics. Using this model, illudin S demonstrates strong anticancer effects but exhibits high toxicity, particularly in the lung and liver, indicating a narrow therapeutic window. Roridin E demonstrates potent activity at low concentrations but exhibits high toxicity, especially in the liver and skin. Additionally, morphological analysis is performed to predict drug delivery and distribution characteristics, revealing anisotropic remission and the influence of microenvironmental factors on drug response. This study underscores the potential of the binary T-MOC system as an alternative platform for anticancer drug evaluation, enabling efficient preclinical validation while reducing reliance on animal models.

Indexed as

Antineoplastic AgentsBiological ProductsDrug DiscoveryLab-On-A-Chip DevicesTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceAntineoplastic AgentsBiological Productsalternative modelanticancer natural productsbinary tumor‐microenvironment‐on‐a‐chip (binary T‐MOC)new approach methodologies (NAMs)poisonous mushrooms

Identifiers

PMID40719068
PMCPMC12561429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.